Imagine three specialized toolkits—one for storing virus samples, one for safe labs, and one for managing massive data—all working as a single machine. Instead of researchers jumping between different organizations and fighting red tape, they now have a one-stop shop. This makes it much faster to study new viruses and find treatments when a health crisis hits.
During viral outbreaks, research labs face bottlenecks because they cannot quickly scale their operations or share data and samples across borders due to regulatory hurdles.
An integrated online catalogue of services and a coordinated governance structure between three major research infrastructures.
If you are a vaccine developer dealing with the slow setup of high-containment lab access—this project developed an integrated service catalogue that speeds up the pipeline for pre-clinical research. This allows for faster transition from virus identification to candidate testing.
If you are a diagnostic kit manufacturer dealing with fragmented access to viral strains—this project developed a coordinated network of bio-banks and data solutions. This ensures you get the necessary biological materials and data to validate tests quickly.
If you are a bioinformatics software provider dealing with non-standardized life science data—this project developed embedded data management solutions across 11 countries. This provides a structured environment to test and scale data-driven outbreak response tools.
Based on available project data, specific pricing is not listed; however, the project focuses on creating a sustainable alliance and a common service catalogue for users.
Yes, the project integrates three reference research infrastructures (EVA, ERINHA, and ELIXIR) to provide a comprehensive operational capacity for the EU.
Based on available project data, the project is establishing a collaboration framework and a term sheet between the infrastructures to manage their joint operations.
The project provides recommendations for harmonized policies and helps users navigate the complex regulatory environment regarding high-risk pathogens.
The project runs from 2024-01-01 to 2026-12-31, with current work focusing on visibility and the creation of the EVA AISBL.
The consortium is heavily weighted toward research and academic institutions, with 13 research organizations and 6 universities. While industry representation is low at 5% (1 partner), the alliance leverages 21 partners across 11 countries to create a massive cross-border infrastructure for health-tech companies.
Contact the Universite d'Aix Marseille regarding the EVORA Industry Focus Group.
Contact us to connect with the EVORA Industry Focus Group for early access to the service catalogue.
